FDA extends review of Novartis’ MS drug ofatumumabThe FDA has extended its review of Novartis’ potential multiple sclerosis drug ofatumumab, pushing back a decision on the repurposed Share XFDA extends review of Novartis’ MS drug ofatumumabhttps://pharmaphorum.com/news/fda-extends-review-of-novartis-ms-drug-ofatumumab/
